- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Dr. Reddy’s Laboratories Ltd ADR (RDY)
The Dr. Reddy’s Labs ADR share price today is 11.85, view NYSE RDY stock exchange data. Track the latest Dr. Reddy’s Labs ADR share price with real-time updates on RDY stock performance including market cap, day range, 52-week range and dividend yield. Access RDY charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.72
11.86
52 wk Range
11.36
15.67
RDY is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.7211.86
52 wk Range
11.3615.67
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.54%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.54%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RDY Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
13.51
Upside
+14.02%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to drop this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
2 Buy
2 Hold
1 Sell
Ratings:
5 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 13.51
(+14.02% Upside)
Dr. Reddy’s Laboratories Ltd ADR SWOT Analysis
Generics Giant Evolves | Dr. Reddy's outperforms in key markets, with strong growth in North America and India, while advancing its biosimilars pipeline for future expansion |
Financial Health | Robust performance with 12.37% revenue growth and 59.29% gross profit margin. InvestingPro analysis suggests stock undervaluation, indicating potential upside |
Market Dynamics | Stable generic drug pricing provides solid foundation for core business, allowing focus on volume growth and market share expansion in competitive landscape |
Analyst Outlook | Overweight rating maintained. Price targets range from $17 to $87, reflecting varied perspectives on Dr. Reddy's growth potential in generics and biosimilars |
Dr. Reddy’s Laboratories Ltd ADR Earnings Call Summary for Q1/2027
- Dr. Reddy's Q1 revenue fell 5.6% YoY to $853M, missing estimates; EPS of $0.06 missed forecast by 33%, driving stock down 7.76% to near 52-week low.
- Semaglutide API issues triggered INR 240 crore provision and production halt; commercial supply expected to resume November with 6-7M pens targeted by March.
- Core business excluding lenalidomide posted double-digit growth across markets; management maintains 20% EBITDA margin target for normalized operations.
- Company plans 27 U.S. product launches in FY2027; abatacept biosimilar remains on track for December 2026 FDA approval with no BLA queries received.
- Capex guidance reduced to INR 1,800 crores from INR 2,500-2,700 crores; firm pursues M&A across generics, biosimilars and peptides with deals in advanced stages.
Last Updated: 22-07-2026, 09:04 pm
Read Full TranscriptEarnings
Latest Release
22-07-2026
EPS / Forecast
0.06 / 0.09
Revenue / Forecast
853M / 858.61M
Compare RDY to Peers and Sector
Metrics to compare | RDY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRDYPeersSector | |
|---|---|---|---|---|
P/E Ratio | 28.9x | 30.4x | −0.3x | |
PEG Ratio | −0.69 | 0.78 | 0.00 | |
Price/Book | 2.5x | 3.7x | 2.6x | |
Price / LTM Sales | 2.9x | 3.8x | 3.0x | |
Upside (Analyst Target) | 10.5% | 8.6% | 56.7% | |
Fair Value Upside | Unlock | 4.5% | 9.4% | Unlock |
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Dr. Reddy’s Labs ADR (RDY) Share Price Today?
The Dr. Reddy’s Labs ADR share price today is 11.85.
What is the current Dr. Reddy’s Labs ADR (RDY) share price and day range?
As of 01-08-2026, the Dr. Reddy’s Labs ADR share price is 11.85, with a previous close of 11.83. The share price has ranged from 11.72 to 11.86 today, while the 52-week range spans from 11.36 to 15.67.
What Is the Dr. Reddy’s Labs ADR Market Cap?
As of today, Dr. Reddy’s Labs ADR market cap is 10.01B.
Does Dr. Reddy’s Labs ADR Pay Dividends? What's The Current Dividend Yield?
The Dr. Reddy’s Labs ADR dividend yield is 0.54%.
What Is the Dr. Reddy’s Labs ADR (RDY) Share Price Target?
The average 12-month share price target for Dr. Reddy’s Labs ADR is 13.51, with a high estimate of 15.7806898 and a low estimate of 11.53204738. 2 analysts recommend buying, while 1 suggest selling, with an overall rating of Neutral and +14.02% Upside potential.
What Is Dr. Reddy’s Labs ADR's Earnings Per Share (TTM)?
The Dr. Reddy’s Labs ADR EPS (TTM) is 39.72.
When Is the Next Dr. Reddy’s Labs ADR Earnings Date?
Dr. Reddy’s Labs ADR will release its next earnings report on 23-10-2026.
From a Technical Analysis Perspective, Is RDY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Dr. Reddy’s Labs ADR Trade On?
Dr. Reddy’s Labs ADR is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for Dr. Reddy’s Labs ADR?
The stock symbol for Dr. Reddy’s Labs ADR is "RDY."
How Many Times Has Dr. Reddy’s Labs ADR Stock Split?
Dr. Reddy’s Labs ADR has split 2 times.
How Many Employees Does Dr. Reddy’s Labs ADR Have?
Dr. Reddy’s Labs ADR has 27527 employees.
What Is the RDY Premarket Price?
RDY's last pre-market stock price is 12.24. The pre-market share volume is 4,800.00, and the stock has changed by 0.41, or 3.47%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.